31 oktober 2021: Zie ook dit artikel: https://kanker-actueel.nl/neoadjuvante-chemotherapie-plus-regionale-hyperthermie-bij-patienten-met-gelokaliseerd-hoogrisico-sarcoom-van-de-weke-delen-geeft-minder-recidieven-en-10-procent-betere-overall-overleving-na-5-en-10-jaar.html

december 2004: Bron: Pubmed: Int J Hyperthermia. 2004 Sep;20(6):661-70.

Kleinschalige studie bewijst dat hyperthermie samen met chemokuren bij een recidief van Ewingsarcoom zeker zin kan hebben.

 Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. Fiegl M, Schlemmer M, Wendtner CM, Abdel-Rahman S, Fahn W, Issels RD. Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany.

PURPOSE: To evaluate the efficacy and safety of the combination of ICE (ifosfamide 1.5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy. Patients and methods: Twenty patients with advanced STS of different histological sub-types were treated with the ICE regimen with 13 patients receiving additional RHT. A median of four courses of ICE were administered with RHT on days 1 and 3 (60 min, T(max) 42 degrees C).

RESULTS: The objective response rate was 20%, with four partial responses (all treated with hyperthermia). In addition, two patients showed mixed responses and five patients stable disease. After a median follow-up time of 15 months, median time to progression was 6 months. Progression free rate estimates were 60% and 45% at 3 and 6 months, respectively. Median overall survival for all patients was 14.6 months.

CONCLUSION: These results suggest that ICE alone or combined with RHT shows activity as second-line therapy in doxorubicin-ifosfamide-refractory STS. PMID: 15370821 [PubMed - in process]

Plaats een reactie ...

Reageer op "Hyperthermie: Recidief van Ewingsarcoma behandelen met chemo in combinatie met hyperthermie bewijst zinvol te zijn in kleinschalige studie"

Gerelateerde artikelen

Gerelateerde artikelen

Neoadjuvante chemotherapie >> Hyperthermie: Langjarige overleving >> Hyperthermie: Recidief van >> Hyperthermie blijkt uitstekende >>